πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 13 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12331078

Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast su

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12251440

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12209142

SARS-CoV-2 epitope-targeted peptide immunostimulants

The United States of America as represented by the Secretary of the Army Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11999777

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11993644

Antigen binding molecules targeting SARS-CoV-2

Generate Biomedicines, Inc. Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866407

Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventin

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739137

Single domain antibodies to SARS-CoV-2 nucleocapsid protein

The Government of the United States of America, as represented by the Secretary of the Navy Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11732030

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11479599

Antibodies against SARS-CoV-2 and methods of using the same

Vir Biotechnology, Inc. Β· Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11168128

Antibodies against SARS-CoV-2 and methods of using the same

Vir Biotechnology, Inc. Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10975139

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10954289

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10787501

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted